Please use this identifier to cite or link to this item:
|Title:||An International Dosimetry Exchange for BNCT Part II - Computational Dosimetry Normalizations|
|Authors:||RILEY Kent; BINNS Peter; HARLING Otto; ALBRITTON Ray; KIGER Stead; REZAEI Arash; SKÖLD Kurt; SEPPÄLÄ Tina; SAVOLAINEN Sauli; AUTERINEN Iiro; MAREK Milan; VIERERBL Ladislav; NIEVAART Victor Alexander; MOSS Raymond|
|Citation:||MEDICAL PHYSICS vol. 35 no. 12 p. 5419-5425|
|Publisher:||AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS|
|Type:||Articles in periodicals and books|
|Abstract:||The meaningful sharing and combining of clinical results from different centers in the world performing boron neutron capture therapy (BNCT) requires improved precision in dose specification between programs. To this end absorbed dose normalizations were performed for the European clinical centers at the Joint Research Centre of the European Commission, Petten (The Netherlands), Nuclear Research Institute, Rez (Czech Republic), VTT, Espoo (Finland) and Studsvik, Nyköping (Sweden). Each European group prepared a treatment plan calculation that was benchmarked against Massachusetts Institute of Technology (MIT) dosimetry performed in a large, water-filled phantom to uniformly evaluate dose specifications with an estimated precision of ±2-3%. These normalizations were compared with those derived from an earlier exchange between Brookhaven National Laboratory (BNL) and MIT in the USA. Neglecting the uncertainties related to biological weighting factors, large variations between calculated and measured dose are apparent that depend upon the 10B uptake in tissue. Assuming a boron concentration of 15 µg g-1 in normal tissue, differences in the evaluated maximum dose to brain for the same nominal specification of 10 Gy(w) at the different facilities range between 7.6 and 13.2 Gy(w) in the trials using boronophenylalanine (BPA) as the boron delivery compound and between 9.0 and 11.1 Gy(w) in the two boron sulfhydryl (BSH) studies. Most notably, the value for the same specified dose of 10 Gy(w) determined at the different participating centers using BPA is significantly higher than at BNL by 32% (MIT), 43% (VTT), 49% (JRC) and 74% (Studsvik). Conversion of dose specification is now possible between all active participants and should be incorporated into future multi-center patient analyses.|
|JRC Directorate:||Energy, Transport and Climate|
Files in This Item:
There are no files associated with this item.
Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.